Malignant neoplasm of the endometrium - Hormonal replacement therapy Factor
Last reviewed for CCPS 30 April 1997.
Investigative Documents
Medical Report - Hormone Replacement Medication - Malignant Neoplasm of the Endometrium [MR9086]
Preliminary questions [14041]
1169 — the veteran is a woman.
the veteran has had a course of hormone replacement therapy at some time.8813 the veteran has undergone a course of hormone replacement medication consisting of oestrogen unopposed by progesterone at some time.
the course of hormone replacement medication consisting of oestrogen unopposed by progesterone was undergone for treatment of an illness or injury which is identifiable. the veteran underwent the course of hormone replacement medication consisting of oestrogen unopposed by progesterone for treatment of the identified illness or injury before the clinical onset of malignant neoplasm of the endometrium.14103 — the veteran has established the causal connection between the identified illness or injury for which the course of hormone replacement medication was undergone and VEA service for the clinical onset of malignant neoplasm of the endometrium.
14104 — the veteran has established the causal connection between the identified illness or injury for which the course of hormone replacement medication was undergone and operational service for the clinical onset of malignant neoplasm of the endometrium.
or
14105 — the veteran has established the causal connection between the identified illness or injury for which the course of hormone replacement medication was undergone and eligible service for the clinical onset of malignant neoplasm of the endometrium.
Clinical onset and operational service [14104]
8823 — the identified illness or injury, for which the veteran had hormone replacement therapy, is causally related to operational service.
Clinical onset and eligible service [14105]
8824 — the identified illness or injury, for which the veteran had hormone replacement therapy, is causally related to eligible service.